Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 3, 2012, Pages 361-367

  Miao, Yu ^a   Zhou, Yu Jie ^a   Wang, Zhi Jian ^a   Shi, Dong Mei ^a   Liu, Yu Yang ^a   Zhao, Ying Xin ^a   Fei, Gao ^a   Yang, Shi Wei ^a   Jia, De An ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

chronic kidney disease; drug eluting stent; stent thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865647104     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23464     Document Type: Article

References (34)

1. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223. (Pubitemid 41352109)
2. Zhang F, Ge J, Qian J, et al. Sirolimus-eluting stents in real-world patients with ST-segment elevation acute myocardial infarction. Int Heart J 2007; 48: 303-311. (Pubitemid 47181003)
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008. (Pubitemid 46376800)
4. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
5. Motovska Z, Petr W, Iuri M, et al. Clopidogrel resistance "Live"-the risk of stent thrombosis should be evaluated before procedures. Thromb J 2009; 7: 6.
6. Lambert ND, Sacrinty MT, Ketch TR, et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J 2009; 157: 688-694.
7. de la Torre-Hernandez JM, Fernando Alfonso, Felipe Hernández, et al. Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51: 986-990.
8. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008; 155: 687-693.
9. Choi DH, Park KW, Yang HM, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol 2010; 146: 174-181.
10. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944. (Pubitemid 44484685)
11. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 1): S1-S266.
12. Buonamici P, Marcucci R, Migliorini A,. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317. (Pubitemid 46891710)
13. Smith SJ, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-e286. (Pubitemid 43879461)
14. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110: e340-e437.
15. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029. (Pubitemid 46376802)
16. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38: 2114-2130. (Pubitemid 33116592)
17. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama 2005; 293: 2126-2130. (Pubitemid 40617065)
18. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007; 50: 501-508. (Pubitemid 47126769)
19. Lambert ND, Sacrinty MT, Ketch TR, et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J 2009; 157: 688-694.
20. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: Success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26: 1180-1187. (Pubitemid 40863124)
21. Kim SS, Jeong MH, Sim DS, et al. Very late thrombosis of a drug-eluting stent after discontinuation of dual antiplatelet therapy in a patient treated with both drug-eluting and bare-metal stents. Korean Circ J 2009; 39: 205-208.
22. Kim SS, Jeong MH, Kim HK, et al. Acute and subacute stent thrombosis in a patient with clopidogrel resistance: A case report. Korean Circ J 2009; 39: 434-438.
23. McCullough PA,. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725-728. (Pubitemid 36308376)
24. Herzog CA, Strief JW, Collins AJ, et al. Cause-specific mortality of dialysis patients after coronary revascularization: Why don't dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant 2008; 23: 2629-2633.
25. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: Insights from the PCI-CURE study. Eur Heart J 2009; 30: 900-907.
26. Rogowski W, Burch J, Palmer S, et al. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: A systematic review and value of information analysis. Health Technol Assess 2009; 13: iii-iv, ix-xi, 1-77.
27. Ivandic BT, Sausemuth M, Ibrahim H, et al. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention. Clin Chem 2009; 55: 1171-1176.
28. Lee K, Lee SW, Lee JW, et al. The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J 2009; 39: 512-518.
29. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516. (Pubitemid 46517957)
30. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008; 155: 687-693.
31. Dasgupta A, Steinhubl SR, Bhatt DL, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009; 103: 1359-1363.
32. Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-1295.
33. Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146.
34. Zhang RY, Zhu BZ, Zhang Q, et al. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. Int J Cardiol 2009; 136: 72-79.